Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab Monotherapy and Combination Therapy in Advanced or Metastatic Colorectal Cancer
NCT05379595Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of amivantamab in colorectal cancer (CRC), sponsored by Janssen Pharmaceutical. Started Jul 2022; status: recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05379595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379595.